The HHS estimates that 18 drugs corresponding with 35 applications that are behind on confirmatory trials cost Medicare Part B and Part D about $14 billion, Medicare Part C $5.9 billion and Medicaid $3.6 billion.
The accelerated approval process is meant to propel life-saving drugs through the approval process faster, according to the FDA. Following the agency’s approval, drugmakers are then instructed to perform confirmatory trials after the treatment hits the market. But these tests aren’t always on track, the HHS said.
“For a variety of reasons, sponsors do not always complete trials promptly,” the Office of Inspector General said in a Sept. 29 news release. “This can result in drugs staying on the market — and being administered to patients — for years without the predicted clinical benefit being verified. And insurers — including Medicare and Medicaid — paying billions for treatments that are not verified to have clinical benefit.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.